Tumor-derived urinary exosomal long non-coding RNAs as diagnostic biomarkers for bladder cancer

Abbastabar, Maryam; Sarfi, Mohammad; Golestani, Abolfazl; Karimi, Ali; Pourmand, Gholamreza; Khalili, Ehsan

doi:10.17179/excli2019-1683

Cited by 22 publications

(11 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other panels, detecting urinary lncRNAs, such as UCA1-201, UCA1-203, MALAT1 or HOTAIR lncRNAs, yielded greater sensitivity and specificity (43.5–100% and 72–100%, respectively) than those targeting serum lncRNAs, but those too need further research and trials before taken in consideration for any further clinical application [ 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 ].…”

Section: Resultsmentioning

confidence: 99%

The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers—What Should a Urologist Really Know?

Malinaric

Mantica

Monaco

et al. 2022

IJERPH

View full text Add to dashboard Cite

The aim of this review is to analyze and describe the current landscape of bladder cancer diagnostic and surveillance biomarkers. We researched the literature from 2016 to November 2021 to find the most promising new molecules and divided them into seven different subgroups based on their function and location in the cell. Although cystoscopy and cytology are still the gold standard for diagnosis and surveillance when it comes to bladder cancer (BCa), their cost is quite a burden for national health systems worldwide. Currently, the research is focused on finding a biomarker that has high negative predictive value (NPV) and can exclude with a certainty the presence of the tumor, considering missing it could be disastrous for the patient. Every subgroup has its own advantages and disadvantages; for example, protein biomarkers cost less than genomic ones, but on the other hand, they seem to be less precise. We tried to simplify this complicated topic as much as possible in order to make it comprehensible to doctors and urologists that are not as familiar with it, as well as encourage them to actively participate in ongoing research.

show abstract

Section: Resultsmentioning

confidence: 99%

The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers—What Should a Urologist Really Know?

Malinaric

Mantica

Monaco

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…For instance, the published studies focusing on the discovery of EV-based biomarkers in BC report different candidates. Nevertheless, PCAT-1 and PRMT5 were shown to be present both in serum and urine [ 59 , 60 , 61 , 80 ]. Additionally, uEV-derived PCAT-1, MALAT-1, and EPS8L2 are represented in different studies [ 59 , 60 , 61 , 69 , 72 , 78 ].…”

Section: Discussionmentioning

confidence: 99%

“…Nevertheless, PCAT-1 and PRMT5 were shown to be present both in serum and urine [ 59 , 60 , 61 , 80 ]. Additionally, uEV-derived PCAT-1, MALAT-1, and EPS8L2 are represented in different studies [ 59 , 60 , 61 , 69 , 72 , 78 ]. The lack of overlapping may be explained by differences in experimental design, such as the preprocessing conditions or the EV isolation method, as well as the dissimilar composition and size of the patient cohorts [ 82 , 83 , 84 ].…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, PCAT-1 and MALAT1 levels were associated with shorter recurrence-free survival in NMIBC patients [ 60 ]. Using a commercial RT-qPCR precipitation, Abbastabar et al found that T1 and T2 BC patients displayed higher ANRIL and PCAT-1 levels in uEVs compared to HC, achieving 46.67 % sensitivity and 87.5% specificity for ANRIL and 43.3% sensitivity and 87.5% specificity for PCAT-1 [ 59 ]. In another study, using sequencing for RNA profiling, Chen et al found that uEVs’ TERC levels were higher in BC patients than in HC, with a diagnostic performance of 78.65% sensitivity and 77.78% specificity, which is considerably higher than that of the NMP22 (FDA-approved) test and urine cytology.…”

Section: Evs In Bcmentioning

confidence: 99%

See 1 more Smart Citation

Extracellular Vesicles as Potential Bladder Cancer Biomarkers: Take It or Leave It?

Teixeira-Marques

Lourenço

Oliveira

et al. 2023

IJMS

View full text Add to dashboard Cite

Bladder cancer (BC) is the 10th most frequently diagnosed cancer worldwide. Although urine cytology and cystoscopy are current standards for BC diagnosis, both have limited sensitivity to detect low-grade and small tumors. Moreover, effective prognostic biomarkers are lacking. Extracellular vesicles (EVs) are lipidic particles that contain nucleic acids, proteins, and metabolites, which are released by cells into the extracellular space, being crucial effectors in intercellular communication. These particles have emerged as potential tools carrying biomarkers for either diagnosis or prognosis in liquid biopsies namely urine, plasma, and serum. Herein, we review the potential of liquid biopsies EVs’ cargo as BC diagnosis and prognosis biomarkers. Additionally, we address the emerging advantages and downsides of using EVs within this framework.

show abstract

“…However, considering precipitation as a method of sEV separation from as complex biofluid as serum, a more detailed functional study concerning the method of transport of selected lncRNAs is needed (Zhang S. et al, 2019). A distinct set of sEV lncRNAs, including the aforementioned PCAT-1, in urine samples of the BCa patients with promising diagnostic performance was found by Abbastabar et al (2020) Their results have shown ANRIL and PCAT-1 potential for low-grade (T1 and T2) detection. The sensitivity and specificity of those markers alone were promising (ANRIL: 46.67 and 87.5%; PCAT-1: 43.33 and 87.5%); however, a study group was relatively small and required confirmation on a larger group.…”

Section: Lncrnamentioning

confidence: 92%

Small extracellular vesicles as a multicomponent biomarker platform in urinary tract carcinomas

Szeliski

Drewa

Pokrywczyńska

2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Extracellular vesicles are a large group of nano-sized vesicles released by all cells. The variety of possible cargo (mRNAs, miRNAs, lncRNAs, proteins, and lipids) and the presence of surface proteins, signaling molecules, and receptor ligands make them a rich source of biomarkers for malignancy diagnosis. One of the groups gathering the most interest in cancer diagnostic applications is small extracellular vesicles (sEVs), with ≤200 nm diameter, mainly composed of exosomes. Many studies were conducted recently, evaluating the diagnostic potential of sEVs in urinary tract carcinomas (UTCs), discovering and clinically evaluating various classes of biomarkers. The amount of research concerning different types of UTCs understandably reflects their incidence. sEV cargos getting the most interest are non-coding RNAs (miRNA and lncRNA). However, implementation of other approaches such as metabolomic and proteomic analysis is also evaluated. The results of many studies indicate that sEVs have an essential role in the cancer process and possess many possible diagnostic and prognostic applications for UTC. The relative ease of obtaining biofluids rich in sEVs (urine and blood) confirms that sEVs are essential for UTC detection in the liquid biopsy approach. A noticeable rise in research quality is observed as more researchers are aware of the research standardization necessity, which is essential for considering the clinical application of their findings.

show abstract

Tumor-derived urinary exosomal long non-coding RNAs as diagnostic biomarkers for bladder cancer

Cited by 22 publications

References 47 publications

The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers—What Should a Urologist Really Know?

The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers—What Should a Urologist Really Know?

Extracellular Vesicles as Potential Bladder Cancer Biomarkers: Take It or Leave It?

Small extracellular vesicles as a multicomponent biomarker platform in urinary tract carcinomas

Contact Info

Product

Resources

About